The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

The Centres for Medicare and Medicaid Services on Friday said that it did not move forward with a proposal put forward by the ...

HYDERABAD (Reuters) - Danish drugmaker Novo Nordisk is looking at an early launch ... a competitive price to Lilly's once-weekly Mounjaro injection, which costs about $50 for a 5 milligram vial ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

which has been confirmed as ingenuine by Ozempic manufacturer Novo Nordisk. Any pens marked with the batch number should be taken to a local pharmacy for safe disposal, the TGA said. Counterfeit ...